AstraZeneca’s Imfinzi Posts Positive Phase III Liver Cancer Data, Shares Slip on Geopolitical Fears
AstraZeneca's Imfinzi achieved positive Phase III results in unresectable liver cancer, positioning the immunotherapy to target a market with limited treatment options and potential multibillion-dollar sales. Shares fell alongside half of the FTSE 100 top 20 names, including defence and gold miners, as investors weighed escalating US-Iran tensions.
1. Positive Phase III Liver Cancer Data
AstraZeneca announced its immune checkpoint inhibitor Imfinzi delivered positive results in a Phase III trial for unresectable hepatocellular carcinoma, where current treatment options are scarce. The data support potential expansion of Imfinzi's label and could drive multibillion-dollar sales growth in hepatic oncology.
2. Share Reaction and Market Drivers
On April 7, AstraZeneca's shares underperformed, falling with half of the FTSE 100 top 20 stocks as investors assessed escalating US-Iran geopolitical risks. The decline mirrored broader market pressure on cyclical and defence names, indicating risk-off sentiment weighed on drugmakers.